Latest news with #Irvine
Yahoo
a day ago
- Health
- Yahoo
Beta Bionics Announces Agreement with Abbott to Integrate the iLet Bionic Pancreas with Abbott's Future Dual Glucose-Ketone Sensor
IRVINE, Calif., June 19, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc., a pioneering leader in the development of advanced diabetes management solutions, announced its intention to integrate its iLet Bionic Pancreas automated insulin delivery (AID) system with Abbott's future dual glucose-ketone sensor in the U.S. The iLet represents a significant advancement in diabetes care as the first and only AID system that makes 100% of insulin dosing decisions automatically. With the iLet, people living with diabetes can achieve excellent clinical outcomes without the burden of carb counting* or manual insulin correction calculations. The system currently supports Abbott's FreeStyle Libre® 3 Plus continuous glucose monitoring sensor, and this future design further extends the collaboration between Beta Bionics and Abbott, reinforcing their shared commitment to bringing cutting-edge diabetes solutions to the market. 'This integration holds great promise for further enhancing real-time decision-making support for people living with diabetes,' said Sean Saint, President and CEO of Beta Bionics. 'As the benchmark in automated insulin delivery systems, the iLet will naturally integrate with Abbott's future dual glucose-ketone sensor as soon as it becomes commercially available.' *User must be carb aware About Beta BionicsBeta Bionics is a commercial-stage medical technology company dedicated to simplifying diabetes management and improving outcomes for people requiring insulin therapy. By leveraging advanced adaptive algorithms, Beta Bionics has developed the iLet® Bionic Pancreas—the first FDA-cleared insulin delivery device with a fully autonomous insulin dosing algorithm. Designed to significantly enhance health outcomes and quality of life across a broad spectrum of individuals with diabetes, the iLet sets a new standard in diabetes care. For more information, visit Important Safety Information Product for prescription only. For important safety information, please visit Investor Relations Contact:ir@ Media and Public Relations Contact:media@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a day ago
- Business
- Yahoo
CTC Global Builds Up Policy and Grid Strategy Team with Addition of Paige Rodrigues
IRVINE, Calif., June 19, 2025--(BUSINESS WIRE)--CTC Global Corporation, the world's leading developer and manufacturer of high-capacity advanced conductors, is pleased to announce the addition of Paige Rodrigues as Senior Manager, Policy and Grid Strategy. In this role, Rodrigues will help drive CTC Global's state and federal policy efforts as well as initiatives with utilities and grid operators. Rodrigues joins CTC Global from Americans for a Clean Energy Grid, where she led the coalition's advocacy at the Federal Energy Regulatory Commission and engaged the U.S. Department of Energy on transmission policy issues. Previously, she served in the office of a U.S. Senator, leading legislative and oversight efforts on grid and transmission issues. Rodrigues holds a Bachelor of Arts degree in Government and Politics from the University of Maryland. CTC Global Chief Policy and Grid Strategy Officer Theodore Paradise stated, "We are excited to welcome Paige to our team. Her background in energy policy, her experience with industry stakeholders, and her deep understanding of energy regulation make her a strong addition to our team." About CTC Global: CTC Global is accelerating access to energy as the world's leading manufacturer of high-capacity advanced conductors. For over two decades, CTC Global has helped communities meet their energy needs and manage the risks associated with legacy transmission infrastructure. Today, over 300 utilities and industrial customers in over 65 countries and 30 U.S. states trust CTC to safely and quickly deploy solutions that add the greatest amount of electricity at the lowest capital cost. Headquartered in Irvine, California, over half of CTC Global's manufacturing capacity is U.S.-based. Its global operations are supported by five manufacturing facilities and an extensive network of partners around the world. CTC Global's advanced conductor is the most responsible and innovative solution to double capacity and improve reliability at scale. For more information, visit View source version on Contacts CTC GlobalTyler Dalton+1 (949) 428-8500tdalton@ DGA Group+1 212 466 6450 x 0ctc@
Associated Press
2 days ago
- Business
- Associated Press
Dr. James Y. Wang Joins Epicutis as Chairman of the Scientific Advisory Board
Harvard-Trained Dermatologist Brings Expertise to Biotech Skin Health Brand IRVINE, Calif., June 18, 2025 /PRNewswire/ -- Epicutis, a pioneering biotech skincare brand known for its science-backed, clean formulations that prioritize skin health over beauty, proudly announces the appointment of Dr. James Y. Wang as Chairman of its Scientific Advisory Board. As a Harvard and UCLA-trained double board-certified dermatologist and dermatopathologist, Dr. Wang brings a wealth of expertise in medical and aesthetic dermatology, reinforcing Epicutis' mission to deliver clinically advanced, non-toxic skincare solutions to market. James Y. Wang, MD, Founder of Metropolis Dermatology, with five locations in California, is widely recognized as a leader in dermatology, specializing in the diagnosis and treatment of skin cancers, psoriasis, eczema, and acne. His impressive academic background includes graduating summa cum laude and Phi Beta Kappa in biology from Washington University in St. Louis, followed by earning his MD from Harvard Medical School and an MBA in healthcare policy from Harvard Business School. 'As a physician, I am committed to evidence-based skincare that is not only safe for all skin types but also effective,' shares Dr. Wang. 'Epicutis represents the perfect fusion of biotechnology and dermatological science, delivering formulations that truly transform skin health at a cellular level, and I am honored to contribute to this next chapter of innovation.' Epicutis was founded on the principles of biotech-driven skincare, leveraging the research of Dr. Jeffrey Stock, a distinguished biophysicist and Princeton University professor. By harnessing proprietary, patented active ingredients, Epicutis formulates small-batch, high-performance skincare products available exclusively through skin professionals. With a focus on transparency, efficacy, and the elimination of unnecessary additives and stabilizers, the brand continues to set new standards in professional skincare. 'We are thrilled to have Dr. Wang join us as Chairman of our Scientific Advisory Board,' said Maxwell Stock, Founder and CEO of Epicutis. 'His deep understanding of dermatological science and passion for cutting-edge innovation align perfectly with our mission to clean up the skincare industry and support clinicians with science-backed, 100% non-toxic products that make a true impact on skin health.' With Dr. Wang's leadership, Epicutis is advancing its commitment to safe, biotech-driven skincare solutions while championing higher regulation to ensure safety and efficacy in an industry often dominated by misleading marketing and mass production. By prioritizing science-backed formulations with patented, highly concentrated therapeutic ingredients, Epicutis is empowering skincare professionals to stand a chance against big beauty. More than just providing innovative products – the brand is actively investing in its partners' success, helping aesthetic businesses grow with exclusive, clinical-grade solutions that drive real results and build lasting patient trust. For more information on Epicutis and its revolutionary approach to skincare, visit About Epicutis Epicutis is a science-based, luxury professional skincare line that treats skin health and not age. Honoring a commitment to clean beauty and fewer ingredients, Epicutis offers science-based skincare using patented active ingredients in small-batch formulations created by expert formulator Masanori Tamura. Epicutis' novel ingredients are developed in-house by a team of scientists at Signum Biosciences utilizing technology discovered by Dr. Jeffry Stock at Princeton University. Signum Biosciences is a biopharmaceutical company focused on the discovery and development of innovative products to address major consumer and medical needs, and the development of compounds and botanical extracts that are mimetics of natural lipid ligands crucial to cellular regulation and signaling. To learn more about Epicutis, visit To learn more about Signum Biosciences, visit View original content to download multimedia: SOURCE Epicutis Skincare
Yahoo
4 days ago
- Business
- Yahoo
Mixed-Signal Devices Launches Industry's Highest Performance RF Synthesizer Up To 22 GHz
New MS4022 Frequency Synthesizer delivers up to 22 GHz output and 25 fs jitter—enabling next-gen radar, communications, and test systems IRVINE, Calif., June 16, 2025 /PRNewswire/ -- IMS 2025 — Mixed-Signal Devices, a leader in multi-gigahertz timing solutions, today announced the MS4022 Frequency Synthesizer, setting a new benchmark in RF performance. With output frequencies up to 22 GHz and ultra-low jitter of just 25 fs RMS, the MS4022 is designed to meet the stringent demands of next-generation radar, wireless infrastructure, phased array, and instrumentation systems. The MS4022 will be demonstrated at the International Microwave Symposium (IMS) 2025, taking place June 15–20 in San Francisco. As RF, defense, and emerging 6G systems push for higher data rates, tighter timing precision, and greater spectral efficiency, engineers face mounting challenges related to noise, system complexity, and scalability. The MS4022 meets these demands with ultra-low phase noise, wideband frequency synthesis, and programmable versatility in a compact form factor. The MS4022 supports seamless locking to external reference sources—including OCXOs, GPS-disciplined oscillators (GPSDOs), and master clock trees—enabling precise synchronization with system-level timing requirements. It provides dual coherent outputs for phase-aligned signal generation, well-suited for applications such as beamforming, MIMO, and multi-channel instrumentation. Integrated jitter attenuation further enhances performance by suppressing reference noise, ensuring exceptionally low phase noise. These capabilities support reliable integration into both stand-alone and distributed architectures where deterministic and high-integrity timing is critical. "With RF systems moving to higher frequencies, legacy analog PLL-based synthesizers can't keep up," said Avi Madisetti, CEO of Mixed-Signal Devices. "The MS4022 utilizes digital synthesis to provide next-generation performance, enabling cleaner signals, tighter phase alignment, and reduced design complexity across critical RF applications." Mixed-Signal Devices MS4022 Frequency Synthesizer Key Features: Frequency Range: 675 MHz to 22 GHz with dual phase-coherent outputs Ultra-Low Jitter: 25 fs RMS (12 kHz to 20 MHz) Reference Flexibility: Supports internal and external reference clocking from 1 PPS up to 750 MHz Interface Options: USB-C for user programmability, SPI optional Applications: FMCW, doppler, and SAR radar, phased array and MIMO RF front-ends, 5G/6G transceiver development, test and measurement systems requiring wideband LO sources, and low-noise clock generation for high-speed converters. With integrated control for output frequency, sweep mode, power level, and step size, the MS4022 simplifies development of modern RF systems requiring precise, wideband signal generation and minimal phase noise distortion. AvailabilityThe MS4022 is sampling now and will be featured at the Mixed-Signal Devices booth 361 at the IEEE MTT-S International Microwave Symposium (IMS), June 15-20, 2025 in San Francisco. Visit for full datasheets, configuration options, and ordering information. To schedule a meeting at IMS or request samples, contact sales@ About Mixed-Signal DevicesMixed-Signal Devices delivers timing and clock solutions for the world's fastest systems. With femtosecond-level jitter, multi-gigahertz performance, and scalable CMOS architectures, our technology enables real-time synchronization across AI data centers, 5G infrastructure, and advanced automotive platforms. Learn more at View original content to download multimedia: SOURCE Mixed-Signal Devices Sign in to access your portfolio
Associated Press
4 days ago
- Business
- Associated Press
You Might Not Qualify for the IRS Fresh Start Program Without These 3 Documents - Clear Start Tax Shares a Checklist
Clear Start Tax Outlines the Key Documents Required for IRS Fresh Start Eligibility and Why Incomplete Files Often Lead to Rejection IRVINE, CA / ACCESS Newswire / June 16, 2025 / If you're hoping to reduce, resolve, or even eliminate your IRS tax debt through the IRS Fresh Start Program, there is one thing you need to know before anything else: documentation is everything. According to Clear Start Tax, thousands of taxpayers are denied relief or face delays simply because they cannot provide the three basic financial records the IRS requires to evaluate Fresh Start eligibility. The firm warns that even if someone qualifies for programs like Offer in Compromise or Currently Not Collectible, missing paperwork can derail the process or lead to automatic rejection. 'The IRS won't evaluate hardship based on what you say - they base it on what you can prove,' said the Head of Client Solutions at Clear Start Tax. 'And most people don't realize how critical their documentation is until it's too late.' The Three Essential Documents the IRS Requires for Fresh Start Program Whether you are applying for a settlement, hardship status, or any form of Fresh Start relief, Clear Start Tax says these three documents are non-negotiable: Without this full financial snapshot, the IRS cannot properly assess eligibility or approve a resolution plan. By answering a few simple questions, taxpayers can find out if they're eligible for the IRS Fresh Start Program and take the first step toward resolving their tax debt. Why the IRS Demands Full Financial Disclosure The IRS uses your financial documents to determine your reasonable collection potential - essentially, what they believe you can afford to pay. If you cannot show your actual income, assets, and expenses, they may: Clear Start Tax emphasizes that even honest taxpayers get penalized for incomplete submissions. How Clear Start Tax Simplifies the Process Most taxpayers find the paperwork confusing and overwhelming. That's why Clear Start Tax streamlines the process from the very beginning. Their team walks clients through each document, helps gather the correct format, and ensures every form meets IRS compliance standards. From collecting pay stubs and lease agreements to calculating self-employment income, Clear Start Tax takes the guesswork out of what the IRS wants - and when they want it. 'We make sure clients submit a clean, complete package,' said the Head of Client Solutions at Clear Start Tax. 'That means fewer delays, fewer rejections, and faster relief.' About Clear Start Tax Clear Start Tax is a full-service tax liability resolution firm that serves taxpayers throughout the United States. The company specializes in assisting individuals and businesses with a wide range of IRS and state tax issues, including back taxes, wage garnishment relief, IRS appeals, and offers in compromise. Clear Start Tax helps taxpayers apply for the IRS Fresh Start Program, providing expert guidance in tax resolution. Fully accredited and A+ rated by the Better Business Bureau, the firm's unique approach and commitment to long-term client success distinguish it as a leader in the tax resolution industry. Need Help With Back Taxes? Click the link below: (888) 710-3533 Contact Information Clear Start Tax Corporate Communications Department [email protected] (949) 535-1627 SOURCE: Clear Start Tax press release
